AstraZeneca To Launch Phase I Trial Of Liver Cancer Drug Developed In China
This article was originally published in PharmAsia News
Executive Summary
An AstraZeneca drug said to be the first of its kind to be developed in China by a multinational drug maker is about to undergo clinical trials to see if it is effective for treating liver cancer. The disease is China's second-largest killer, lung cancer being first. China's State FDA has approved the Phase I clinical trial, a step somewhat unusual since China often relies on results from a first-stage abroad before approving one locally. The drug was developed through global chemistry research by the company's Chinese innovation center, its sole research facility in Asia. (Click here for more